MétaCan
Menu
Back to cohort
Record W4392785398 · doi:10.1093/cid/ciae143

Type 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Pooled Analysis From 72 Global Studies

2024· article· en· W4392785398 on OpenAlexafffund
Raphael J. Landovitz, Tao Li, Juan Yang, Melanie de Boer, Christoph C Carter, Moupali Das, Jared M. Baeten, Albert Liu, Karen W. Hoover, Connie Celum, Beatriz Grinsztejn, Sheldon Morris, Darrell P. Wheeler, Kenneth H. Mayer, Sarit A. Golub, Linda‐Gail Bekker, Souleymane Diabaté, Elske Hoornenborg, Janet J. Myers, Ashley A. Leech, Sheena McCormack, Philip A. Chan, Michael Sweat, Robert M. Grant, Chris Beyrer, Joelle Brown, Jesse L. Clark, Paul W. Colson, Robyn Eakle, Jason E. Farley, Charlene Flash, Jorge Gallardo, Geoffrey S. Gottlieb, Alexandre Grangeiro, Renee Heffron, Sybil Hosek, Mark Hull, John Idoko, Irene Inwani, Helen Koenig, Ann Kurth, Shui Shan Lee, Kenneth Mayer, Souleymane Mboup, Jaimie P. Meyer, Anthony Mills, Andrew Mujugira, Pietro Pala, John Phoenix, Janice Piatt, Darren Russell, Eduard J. Sanders, R. Scott, Jae Sevelius, Hong Shang, Marc Siegel, Shobha Swaminathan, Vivian Robert Tamayo, Darrell H. S. Tan, Allan W. Taylor, Béa Vuylsteke

Bibliographic record

VenueClinical Infectious Diseases · 2024
Typearticle
Languageen
FieldMedicine
TopicHIV/AIDS drug development and treatment
Canadian institutionsCentre hospitalier de l'Université Laval
FundersDavid Geffen School of Medicine, University of California, Los AngelesNational Institute of Mental HealthNational Institute on Alcohol Abuse and AlcoholismMedical Research CouncilUniversity of California, San FranciscoUniversity of Illinois at Urbana-ChampaignSubstance Abuse and Mental Health Services AdministrationNational Institutes of HealthUniversidad Nacional Mayor de San MarcosInternational AIDS SocietyUniversidade de São PauloChinese University of Hong KongNational Institute for Health and Care ResearchInstituut voor Tropische GeneeskundeEuropean and Developing Countries Clinical Trials PartnershipCenters for Disease Control and PreventionAuckland District Health BoardRhode Island Department of HealthWellcome TrustLondon School of Hygiene and Tropical MedicineImperial College LondonJohns Hopkins UniversityUniversity of WashingtonGilead SciencesUniversity of TorontoYale UniversityGeorge Washington UniversitySanofiChina Medical UniversityBristol-Myers SquibbCalifornia Institute for Regenerative MedicinePfizerViiV HealthcareBill and Melinda Gates FoundationUniversity of PennsylvaniaUnited States Agency for International DevelopmentMagee-Womens Research InstituteGeorgetown UniversityDoris Duke Charitable Foundation
KeywordsEmtricitabineMedicineIncidence (geometry)DiscontinuationPre-exposure prophylaxisInternal medicineAdverse effectTenofovirDrug resistanceHuman immunodeficiency virus (HIV)Viral loadAntiretroviral therapyMen who have sex with menVirology

Abstract

fetched live from OpenAlex

BACKGROUND: Oral pre-exposure prophylaxis (PrEP) with emtricitabine/tenofovir disoproxil fumarate (F/TDF) has high efficacy against HIV-1 acquisition. Seventy-two prospective studies of daily oral F/TDF PrEP were conducted to evaluate HIV-1 incidence, drug resistance, adherence, and bone and renal safety in diverse settings. METHODS: HIV-1 incidence was calculated from incident HIV-1 diagnoses after PrEP initiation and within 60 days of discontinuation. Tenofovir concentrations in dried blood spots (DBS), drug resistance, and bone/renal safety indicators were evaluated in a subset of studies. RESULTS: Among 17 274 participants, there were 101 cases with new HIV-1 diagnosis (.77 per 100 person-years; 95% confidence interval [CI]: .63-.94). In 78 cases with resistance data, 18 (23%) had M184I or V, 1 (1.3%) had K65R, and 3 (3.8%) had both mutations. In 54 cases with tenofovir concentration data from DBS, 45 (83.3%), 2 (3.7%), 6 (11.1%), and 1 (1.9%) had average adherence of <2, 2-3, 4-6, and ≥7 doses/wk, respectively, and the corresponding incidence was 3.9 (95% CI: 2.9-5.3), .24 (.060-.95), .27 (.12-.60), and .054 (.008-.38) per 100 person-years. Adherence was low in younger participants, Hispanic/Latinx and Black participants, cisgender women, and transgender women. Bone and renal adverse event incidence rates were 0.69 and 11.8 per 100 person-years, respectively, consistent with previous reports. CONCLUSIONS: Leveraging the largest pooled analysis of global PrEP studies to date, we demonstrate that F/TDF is safe and highly effective, even with less than daily dosing, in diverse clinical settings, geographies, populations, and routes of HIV-1 exposure.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.012
metaresearch head score (Gemma)0.010
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: Meta-analysis
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.012
Threshold uncertainty score0.062

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0120.010
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0060.015
Bibliometrics0.0050.005
Science and technology studies0.0000.000
Scholarly communication0.0020.001
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.032
GPT teacher head0.373
Teacher spread0.341 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designMeta-analysis
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations19
Published2024
Admission routes2
Has abstractyes

Explore more

Same venueClinical Infectious DiseasesSame topicHIV/AIDS drug development and treatmentFrench-language works237,207